Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications - Report - MDSpire

Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications

  • By

  • Yong Zhang

  • Ting Wang

  • An-Qi Lyu

  • Fang Zhang

  • Fang-Hui Li

  • Ling-Di Zhao

  • Zi-Bing Wang

  • Yi-Man Shang

  • Bao-Zhen Ma

  • Xiao-Qun Dong

  • Quan-Li Gao

  • April 21, 2026

  • 0 min

Share

Clinical Report: Evaluation of SHR-1210 and Apatinib for Mucosal Melanoma

Overview

Revise to explain the relationship between disease control rate and objective response rate more clearly.

Background

Mucosal melanoma is a rare and aggressive form of melanoma that is often diagnosed at advanced stages due to its hidden anatomical locations. Compared to cutaneous melanoma, mucosal melanoma shows a lower response to immunotherapy, highlighting the need for effective treatment strategies. This study explores a novel combination therapy aimed at improving outcomes for this challenging patient population.

Data Highlights

OutcomeResult
Disease Control Rate (DCR)100% (SD = 13)
Objective Response Rate (ORR)0%
Median Overall Survival (OS)29.9 months (95% CI 15.26-44.54)
Median Progression-Free Survival (PFS)5.17 months (95% CI 3.27-10.27)

Key Findings

  • The combination of SHR-1210 and Apatinib achieved a 100% disease control rate in the study cohort.
  • No objective responses were observed, indicating a need for further investigation into treatment efficacy.
  • The median overall survival was reported at 29.9 months, suggesting potential for prolonged survival.
  • Common adverse effects included hand and foot induration and desquamation, with one case of severe liver dysfunction.
  • This study emphasizes the importance of exploring combination therapies for advanced mucosal melanoma.

Clinical Implications

Strengthen the discussion on the implications of the findings regarding efficacy.

Conclusion

Reinforce the call for further research and specify potential future directions.

References

  1. The ASCO Post, 2012 -- MEK Inhibitor Reduces Progression of BRAF-mutated Melanoma and Might also Benefit Others
  2. The ASCO Post, 2015 -- Treatment Paradigm in Advanced Melanoma Poised for Change… Again
  3. PubMed -- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
  4. PubMed -- Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis
  5. The ASCO Post — Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer
  6. The ASCO Post — Adding Immunotherapy to BRAF/MEK Inhibition in BRAF V600–Mutant Melanoma: First Step on the Journey
  7. NCCN Head & Neck Cancers guideline, 2026
  8. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis - PubMed
  9. Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis - PubMed

Original Source(s)

Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications

  • by Yong Zhang, Ting Wang, An-Qi Lyu, Fang Zhang, Fang-Hui Li, Ling-Di Zhao, Zi-Bing Wang, Yi-Man Shang, Bao-Zhen Ma, Xiao-Qun Dong, Quan-Li Gao

  • April 21, 2026

Related Content

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

FLASH Radiotherapy Maintains Systemic and Tissue Balance While Effectively Targeting Tumors

Modeling the Genetics of Uveal Melanoma

Researchers have developed a genetically engineered mouse model that mirrors the genetic evolution of uveal melanoma

  • April 21, 2026

  • 3 min